Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous Endorem-labelled mononuclear cells
- Development stage
- Unknown
- Modality
- Cell Therapies
- Administration
- Intravenous, Intra-arterial, Intramuscular, Intracoronary, Intramyocardial
01
Overview
Autologous Endorem-labelled mononuclear cells are a cell therapy product consisting of a patient's own (autologous) peripheral blood or bone marrow-derived mononuclear cells that have been ex vivo labelled with Endorem, a superparamagnetic iron oxide (SPIO) nanoparticle contrast agent. The primary purpose of this labelling is to enable noninvasive tracking of the administered therapeutic cells using magnetic resonance imaging (MRI). Mononuclear cell populations include lymphocytes (T, B, NK cells), monocytes, and sometimes progenitor or stem cell subsets. The SPIO labelling does not significantly impair cell viability or migratory function. This approach is primarily used in clinical research to monitor the biodistribution and fate of infused therapeutic immune or stem/progenitor cells in regenerative medicine and immunotherapy trials[3][6][10].
- Other names
- autologous SPIO-labelled mononuclear cellsautologous superparamagnetic iron oxide-labelled mononuclear cells
Beyond the preview
Go deeper on autologous Endorem-labelled mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous Endorem-labelled mononuclear cells.